Patient-derived Xenograft Models (PDX)

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Established</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>10</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
</tr>
<tr>
<td>Cholangio</td>
<td>2</td>
</tr>
<tr>
<td>Colon</td>
<td>182</td>
</tr>
<tr>
<td>Gastric</td>
<td>2</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>27</td>
</tr>
<tr>
<td>Glioma*</td>
<td>27</td>
</tr>
<tr>
<td>Gynecologic</td>
<td></td>
</tr>
<tr>
<td>Endometrial</td>
<td>8</td>
</tr>
<tr>
<td>Ovarian</td>
<td>10</td>
</tr>
<tr>
<td>Haematological</td>
<td></td>
</tr>
<tr>
<td>ALL*</td>
<td>9</td>
</tr>
<tr>
<td>AML</td>
<td>9</td>
</tr>
<tr>
<td>B-Cell Lymphoma</td>
<td>10</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>39</td>
</tr>
<tr>
<td>Lung</td>
<td></td>
</tr>
<tr>
<td>NSCL</td>
<td>47</td>
</tr>
<tr>
<td>SCL</td>
<td>2</td>
</tr>
<tr>
<td>Melanoma</td>
<td>13</td>
</tr>
<tr>
<td>Sarcoma*</td>
<td>24</td>
</tr>
<tr>
<td>Urological</td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td>1</td>
</tr>
<tr>
<td>Prostate</td>
<td>1</td>
</tr>
<tr>
<td>Renal</td>
<td>32</td>
</tr>
</tbody>
</table>

* also from pediatric patients

Database includes:

- Molecular data
  - gene expression profiles
  - panel sequencing data (NGS)
- Response data
  - classical chemotherapy
  - targeted therapy
  - hormone therapy
- Patient data
  - disease status
  - histology
  - gender, age

For more details and registration visit our website:
www.epo-berlin.com

expert service in preclinical research & development of new cancer drugs

Founded in 1997, EPO develops customized testing procedures. EPO currently has 40 employees and more than 150 clients from scientific institutes, biotech and pharmaceutical companies worldwide.

Please contact us for your specific requests, or visit our Website: www.epo-berlin.com

Experimental Pharmacology & Oncology Berlin-Buch GmbH
Robert-Bosse-Str. 10
13125 Berlin
Tel.: +49 30 9489 4480
Fax: +49 30 9489 4441

Dr. Jens Hoffmann (CEO)
Jens.Hoffmann@epo-berlin.com

Prof. Dr. Wolfgang Walther (CSC)
wolfgang.walther@epo-berlin.com

Dr. Kristin Fichtner (CSC)
kfichtner@epo-berlin.com
We offer the right models for each preclinical development phase.

**Target identification and validation**
- Large panels of tumor models
- Corresponding repositories of tumor materials (GTC, snap frozen, FFPE, DNA, RNA)
- Extensive data about histology, genetic profile, drug sensitivity and mutations

**Lead optimization**
- Tumor models with defined target expression for screening and comparison with standards
- Implementation of transgenic techniques
- PK/PD/Tox
- Pathology

**Translational research**
- Extensively characterized patient derived xenografts for applied studies (preclinical phase II)
- Implementation of personalized therapy
- Experimental imaging
- Immuno-oncology

More than 500 tumor models are available
Including: drug resistant tumor models, metastasis models, orthotopic tumor models

**Preclinical Testing & Pharmacology**
- Cytotoxic compounds
- Targeted therapeutics
- Biological drugs
- Oncolytic bacteria & viruses
- Gene and cell therapeutics
- Radio-isotopes
- Vaccines
- Immune modulators and checkpoint inhibitors

**Technologies**
- **Cell & Molecular Biology**
  - 2D and 3D Tumor and stem cell cultures
  - PCR and next generation sequencing
- **Radiation**
  - Compact X-Ray Irradiation System: Faxitron® Multibrad 160
  - Tumor Irradiation
  - Immune system depletion
- **Micro-Ultrasound**
  - Ultrasound Imaging System: Vevo® 2100
  - Visualization of orthotropic tumors
  - Guided tumor transplantation
- **Bioluminescence**
  - Non-invasive imaging of ongoing biological processes
  - In vivo monitoring of orthotopic tumors
- **Flow cytometry**
  - Flow cytometry allows
  - Detection and characterization of tumor and stem cells
  - Immunophenotyping of blood, organs and tumor
- **Pathology**
  - Experimental pathology and histopathology services
  - Autopsy & histopathology
  - Immunohistochemistry

Our services and experiences cover the following fields of preclinical research.

The EPO tumor models provide a unique & outstanding source for your cancer research projects.

Next page → Overview of our patient-derived xenografts